Actively Recruiting

Phase Not Applicable
Age: 18Years - 85Years
All Genders
ID05230446

Prospective Evaluation of Complete Revascularization Using PCI with OCT Guidance in Patients With Multivessel Coronary Artery Disease Excluding Chronic Total Occlusions

Led by Erasmus Medical Center · Updated on 2022-02-09

609

Participants Needed

1

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating clinical outcomes after complete revascularization using percutaneous coronary intervention (PCI) with imaging guidance by optical coherence tomography (OCT) in patients who have multivessel coronary artery disease, including those with stable angina, silent ischemia, or non-ST segment elevation acute coronary syndrome (NSTE-ACS). This prospective, multicenter, non-randomized, single-arm study aims to compare results against a performance goal derived from past coronary artery bypass grafting (CABG) outcomes. The study uses PCI guided by OCT imaging before and after stent placement to improve accuracy and prevent complications such as malapposition or dissections. All patients receive drug-eluting stents according to specific guidelines and manufacturer instructions. This single-arm trial does not randomize participants and focuses on patients with multivessel disease excluding chronic total occlusions. Participants will be monitored for major adverse cardiac and cerebrovascular events (MACCE) including death, stroke, myocardial infarction, and repeat revascularization at one year after the initial procedure. Secondary assessments include these outcomes at 30 days, 2 years, and 5 years, as well as bleeding events and need for renal replacement therapy. Follow-up visits and study procedures will assess safety and effectiveness over the long term, with participation lasting up to five years post intervention.

CONDITIONS

Brief Title

PRospective Evaluation of Complete Revascularization in Patients With multiveSsel Disease Excluding chroNic Total Occlusions

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 85 years
  • Candidates suitable for drug-eluting stent treatment following PCI guidelines and manufacturer's instructions
  • Target lesion characteristics fit the device's instructions for use
  • Willing and able to cooperate with study procedures and follow-up visits
  • Provided informed consent including data privacy authorization
Not Eligible

You will not qualify if you...

  • Age below 18 or above 85 years
  • Single coronary vessel disease
  • No lesion in the left anterior descending artery
  • Cardiogenic shock
  • ST-elevation myocardial infarction (STEMI)
  • Presence of chronic total occlusion lesion for 3 or more months
  • Left main coronary artery disease
  • Unable to give informed consent or life expectancy less than 12 months
  • Allergies or contraindications to contrast agents or study medications
  • Extreme tortuosity of the left anterior descending artery preventing OCT catheter use
  • Enrolled in another investigational device or drug trial without primary endpoint reached
  • Previous coronary artery bypass grafting (CABG)
  • Need for additional cardiac surgery within 6 months
  • Women of childbearing potential without negative pregnancy test, pregnant or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Single procedure day

Participants undergo PCI with OCT guidance to optimize stent placement and improve treatment outcomes.

1 visit (in-person)

Post-operative Follow-up

Duration - Up to 5 years

Participants are monitored for safety and clinical outcomes including major adverse cardiac and cerebrovascular events.

Visits at 30 days, 1 year, 2 years, and 5 years post intervention

Trial Site Locations

Total: 1 location

1

Erasmus Medical Center

Rotterdam, South Holland, Netherlands, 3015 GD

Actively Recruiting

Loading map...

Research Team

R

Roberto Diletti, MD PhD

H

Hala Kakar, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

24 Versus 12-Month Dual Antiplatelet Therapy After Drug-Elut...

Elevated Lipoprotein(a) Level

Actively Recruiting

1 location

A 10-Minute Cardiovascular Magnetic Resonance Protocol for C...

Coronary Artery Disease

Actively Recruiting

1 location

A Longitudinal Cohort of Patients With Acute Coronary Syndro...

Acute Coronary Syndrome

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here